Text Size
S
M
L
Listen
Santen Global
menu
Patients
Healthcare Professionals
Careers
Investors
Listen
Tap on the left to use.
Who We Are
Message
Message from the CEO
Santen’s Corporate Philosophy Framework
Santen’s Corporate Philosophy Framework
History
History of Santen
Corporate Executives
Corporate Executives
Corporate Governance
Corporate Governance
Digital Transformation
Digital Transformation
Policies
Policies and Statements
Company Infomation
Overview / Map
Global Operation
What We Do
MTP
Medium-term Management Plan
Efforts to Enhance Patients' Satisfaction
Efforts to Enhance Product Safety
Efforts to Enhance Product Usability
Efforts to Address Untreated Patients
Research & Development
Research & Development
The Ophthalmic Development Process
Clinical Trial Information
Partnering
Santen's Partnership
Our Partners
Partnering Contact
Production
Production
Safety and Quality Assurance
The Ophthalmic Production Process
Sales & Marketing
Sales & Marketing
Our Stories
Sustainability
Sustainability
Our Sustainability Commitment
Sustainability at Santen
Social
Access to Healthcare
Research & Development in Ophthalmology
Product Quality & Safety
Supply Chain
Human Rights
Talent
Governance
Corporate Governance
Compliance
Ethical Marketing
Risk Management
Information Security
Environment
Environmental initiatives
Measures against Climate Change
Environmental Load Reduction
Biodiversity
Disclosures Based on the TCFD Recommendations
Inclusion
Inclusive Society Santen Promotes
Inclusion Starting from Blind Football
Together with Society
With Employees
Related Information
Participating in the UN Global Compact
Social Contribution Activities
Stakeholder Engagement
Environment Data (up-to-date)
Social Data (up-to-date)
Governance Data (up-to-date)
GRI Standards Content Index
Sustainability Library
External Assessment
News
News
Show All
Press Release
IR News
Information
HOME
News
2022
2022 News
Press Release
IR News
Information
Press Release
11.29.2022
Notice of Personnel Changes
11.21.2022
Santen launches the dry-eye treatment DIQUAS® LX Ophthalmic Solution 3% in Japan - Improved formulation to reduce administration frequency to three-times daily, thus easing patients' burden -
10.26.2022
Santen Strengthens Global Product Supply Base with Completion of Third Building on Site of Shiga Product Supply Center
10.14.2022
Santen Publishes its Annual Integrated Report "Santen Report 2022"
10.06.2022
Santen filing accepted by European Medicines Agency (EMA) for review of application for marketing authorization of the use of STN1013001 cationic emulsion of latanoprost 50?g/mL in glaucoma
Press Release
IR News
12.01.2022
Santen Announces Status of Share Buyback
11.29.2022
Notice of Personnel Changes
11.21.2022
Santen launches the dry-eye treatment DIQUAS® LX Ophthalmic Solution 3% in Japan - Improved formulation to reduce administration frequency to three-times daily, thus easing patients' burden -
11.08.2022
Santen Reports the 2nd Quarter Fiscal 2022 Consolidated Performance
11.08.2022
Notice of Recording of Impairment Loss and Revision of Full-Year Earnings Forecasts
IR News
Information
06.29.2022
Disclosures based on the TCFD recommendations has published
03.25.2022
Santen switches all externally-sourced electricity for its plants and research facility in Japan to renewable energy-based power
Information
News Archive
